Paraná State University of Ponta Grossa-UEPG, Department of Clinical and Toxicological Analysis, Uvaranas Campus, Ponta Grossa-PR, Brazil.
Metabolism. 2012 Oct;61(10):1353-60. doi: 10.1016/j.metabol.2012.03.003. Epub 2012 Apr 3.
HIV infection is exacerbated through additional pro-atherogenic mechanisms related to the processes of immune activation, inflammation, coagulation, and the modification of lipoproteins (e.g., particles of high density lipoprotein), contributing to increased cardiovascular risk. The aim of this study was to analyze the serum concentrations of myeloperoxidase (MPO) and other laboratory parameters in HIV-infected patients treated or not with antiretroviral drugs compared to non-infected individuals.
MATERIALS/METHODS: The study included 154 volunteers: 47 non-infected individuals (control group - CON), 27 infected and untreated individuals (NTARV group) and 80 treated individuals (TARV group). We analyzed the counts of CD4+ lymphocytes and the viral load of the infected patients, along with the blood count, fasting glucose, total serum cholesterol (CHOL), HDL cholesterol, LDL cholesterol, triglycerides, MPO and high-sensitivity C-reactive protein (CRP) of all study participants.
There were significant increases in glucose, CHOL, LDL cholesterol, and triglycerides in the TARV group and significant reductions in the levels of HDL cholesterol for the TARV and NTARV groups. Significantly elevated levels of Hs-CRP were observed only in the TARV group, while levels of MPO were significantly higher in the TARV and NTARV groups compared to the control group. A correlation of MPO with Hs-CRP (r=0.21, p=0.032) was observed for HIV-infected patients, but MPO did not correlate significantly with the other analyzed parameters.
The investigation of early biomarkers for cardiovascular risk evaluation, such as MPO, contributes to the clinical monitoring of HIV-infected individuals. The serum levels of MPO correlated with Hs-CRP and were high in HIV-infected individuals, indicating a possible predictor of cardiovascular events in these patients.
HIV 感染通过与免疫激活、炎症、凝血和脂蛋白（如高密度脂蛋白颗粒）修饰等过程相关的其他促动脉粥样硬化机制而加重，导致心血管风险增加。本研究旨在分析接受或未接受抗逆转录病毒药物治疗的 HIV 感染患者与未感染个体相比，其血清髓过氧化物酶（MPO）浓度和其他实验室参数。
材料/方法：该研究纳入了 154 名志愿者：47 名未感染个体（对照组-CON）、27 名感染未治疗个体（NTARV 组）和 80 名治疗个体（TARV 组）。我们分析了感染患者的 CD4+淋巴细胞计数和病毒载量，以及所有研究参与者的血常规、空腹血糖、总血清胆固醇（CHOL）、高密度脂蛋白胆固醇（HDL-CHOL）、低密度脂蛋白胆固醇（LDL-CHOL）、甘油三酯、MPO 和高敏 C 反应蛋白（hs-CRP）。
TARV 组的血糖、CHOL、LDL-CHOL 和甘油三酯显著升高，TARV 和 NTARV 组的 HDL-CHOL 水平显著降低。仅在 TARV 组观察到 hs-CRP 水平显著升高，而 MPO 水平在 TARV 和 NTARV 组均显著高于对照组。在 HIV 感染患者中，MPO 与 hs-CRP 呈正相关（r=0.21，p=0.032），但与其他分析参数无显著相关性。
对髓过氧化物酶等心血管风险评估的早期生物标志物进行研究有助于对 HIV 感染个体进行临床监测。MPO 的血清水平与 hs-CRP 相关，且在 HIV 感染个体中较高，提示其可能是这些患者心血管事件的预测因子。
